10 Hot Biotech Penny Stocks For Your Watchlist Next Month
Biotech penny stocks are heating up right now. While this began a few months after the onset of Covid, since then, penny stocks in the biotech sector have continued to make headway. One thing to keep in mind is that biotech stocks tend to be some of the most speculative securities out there. Because news is released so frequently, volatility in the biotech sector is always very high. And while this may seem scary at first, on the other side it presents opportunities to take advantage of large and frequent price moves.
Considering that Covid case numbers are the lowest they’re been in months, we could see a resurgence of non-pandemic related biotech penny stocks. With this in mind, investors should consider aspects such as how much capital a company has on hand, what products are in its pipeline, and whether it has any approved compounds or medical devices. This article is a continuation of ‘Best Penny Stocks To Buy Right Now? 5 Biotech Stocks For Your List’. Taking all of this into consideration, here are ten penny stocks that should be on your July 2021 watchlist.
5 More Hot Biotech Penny Stocks to Watch Right Now
- Intec Pharma Ltd. (NASDAQ: NTEC)
- Adial Pharmaceuticals Inc. (NASDAQ: ADIL)
- vTv Therapeutics Inc. (NASDAQ: VTVT)
- MediciNova Inc. (NASDAQ: MNOV)
- Opko Health Inc. (NASDAQ: OPK)
Intec Pharma Ltd. (NASDAQ: NTEC)
A biopharmaceutical penny stock to watch this month is Intec Pharma. This company is working toward developing novel drugs using its proprietary Accordion Pill® Platform Technology. Specifically, NTEC is known for its drug delivery system that utilizes unique characteristics. With biodegradable polymeric films, NTEC can load drugs and other active ingredients onto the compound. It then can mold them into an undulated shape which seals it into a capsule.
This oral drug delivery system has made waves in the pharmaceutical industry. It’s the first of its kind and is designed to improve the delivery and safety of existing drugs. It does this through efficient gastric retention and its release mechanistic technology. This AP drug system releases the drug of choice slowly into the stomach over several hours, making the body absorb it more efficiently and steadily. More and more trials are being conducted in order to prove its functionality, but in the meantime, NTEC could be worth keeping an eye on.
Adial Pharmaceuticals Inc. (NASDAQ: ADIL)
Another pharmaceutical company to watch right now is Adial Pharmaceuticals. This clinical-stage biopharmaceutical company develops therapies to help treat and prevent addiction and other related disorders. Its flagship drug, AD04, is a serotonin-3 receptor antagonist that targets genetic regions. It’s in use in the treatment of Alcohol Use Disorder (AUD) and could have indications in several others.
Recently a Phase 2b clinical trial of AD04 showed that it was effective at reducing AUD. This drug could also lower the effects of Opioid Use Disorder (OUD), gambling, and other addictive ailments. Today ADIL announced its plan to enter the genetic testing market after the U.S. Patent and Trademark Office sent out a Notice of Allowance.
“This new patent related to the use of our genetic diagnostic panel in combination with AD04 for the treatment of AUD and OUD is a major milestone as we believe genetic evaluation of patients can be used to identify individuals that may benefit from AD04.
We have been utilizing the genetic panel covered by this patent in our ongoing ONWARD™ Phase 3 trial, and, given this patent allowance, we anticipate that genetic diagnostics are expected to be an important segment of our commercial strategy going forward.”William Stilley, CEO of Adial Pharmaceuticals
With this big move in mind, it’s no wonder that ADIL stock is gaining so much traction right now.
vTv Therapeutics Inc. (NASDAQ: VTVT)
Today, vTv Therapeutics reported that it will be entering into a business deal with Cantex Pharmaceuticals Inc. This licensing agreement gives Cantex exclusive rights to the worldwide development and commercialization of vTv’s novel product Azeliragon.
This product is an antagonist of RAGE, or the receptor for advanced glycation endproducts. RAGE is a part of a variety of life-threatening cancers and is often associated with high mortality and a decrease in life quality. This oral medication is currently in Phase 2 trials to see its efficacy against this specific effect of cancer.
President and CEO of vTv stated, “RAGE is a highly attractive target for the treatment of a wide spectrum of disorders. We believe Cantex is the right partner to further the development of azeliragon, which vTv had studied in Alzheimer’s disease, in new therapeutic indications. They have deep experience in clinical development and the proven capability of repurposing drug candidates for new indications.” Whether this makes VTVT stock worth watching or not is up to you.
MediciNova Inc. (NASDAQ: MNOV)
MediciNova is a biotech penny stock that we’ve covered numerous times in the past few weeks. In recent news, MediciNova announced positive Phase 2 trial results for MN-166 (ibudilast). This penny stock operates in the alcohol use disorder (AUD) sector and recently saw its work published in the journal, Nature and Translational Psychiatry.
The study worked to test the effect of ibudilast on patient mood, heavy drinking, and neural reward signals of 52 individuals with AUD. It is a two-week, double-blind study that utilized placebo pills. The results revealed that patients who took ibudilast significantly reduced their probability of heavy drinking compared to the patients taking the placebo medication.
These results are optimistic for the company as a whole and could put it on a solid trajectory moving forward. One of the main contributors of the study, Dr. Lara Ray, is continuing to work on proving the functionality of ibudilast in other case studies. Positive news in the biotech industry is not something we see everyday. However, announcements like this occur, it is always a great sign. Given this news, what do you think of MNOV moving forward? Is this a penny stock you want to add to your watchlist?
Opko Health Inc. (NASDAQ: OPK)
The last penny stock on this list is Opko Health, which has been making waves in several recent trading sessions. Only a few weeks ago, OPK announced its plans to sell its facility in Ireland. This sale to Horizon Therapeutics Public Limited Company is worth $65 million, and will proceed pending government approval. The funds gained from this sale will go to further strengthen the international business Opko Health is currently working on.
In addition, this sale will likely improve Opko’s balance sheet which could lead to better investor sentiment in the long term. With a high amount of debt on its books, the ability to reduce its obligations would be a win for the company. In May, OPK made a deal with Japan Tobacco Inc. and Vifor Fresenius Medical Care Renal Pharma to transfer licensing rights to RAYALDEE.
This announcement occurred only a few weeks between its strong Q1 results from April. In the results, higher revenues than expected were seen, indicating positive movement with OPK. All things considered, what do you think about Opko health as a potential penny stock to watch?
Will Biotech Penny Stocks continue to Make Headway?
With penny stocks continuing to heat up, many investors are excited about the future. While biotech tends to be a highly speculative industry, if you know how to use volatility to your advantage, it can be profitable.
Considering that there are hundreds of biotech companies on the list of penny stocks to watch, making a decision can be tough. But, with the internet at our fingertips, finding the best biotech penny stocks to buy can be easier than previously imagined.
To read about the other four stocks on this list, head to Best Penny Stocks To Buy Right Now? 5 Biotech Stocks For Your List